Stemline Therapeutics Inc (STML_old)

NASDAQ
Currency in USD
11.83
0.00(0.00%)
Closed·
Showing Stemline historical data. For real-time data please try another search
Day's Range
11.8212.10
52 wk Range
0.0012.10
Key Statistics
Edit
Prev. Close
11.83
Open
12
Day's Range
11.82-12.1
52 wk Range
0-0
Volume
-
Average Volume (3m)
282.31K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Stemline Therapeutics Inc News & Analysis

Show more

Stemline Therapeutics Inc Company Profile

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed at the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients two years of age and older. The company provides ORSERDU for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, and ESR-1-mutated advanced or metastatic breast cancer. It also develops CD123, which is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma, in combination with other therapies. In addition, the company is developing SL-801, a novel oral small-molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trials for the treatment of solid and hematologic cancers, and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123-targeted therapy; SL-1001, an oral, selective small-molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. The company was incorporated in 2003 and is based in New York, New York. Stemline Therapeutics, Inc. operates as a subsidiary of Berlin-Chemie AG.

Industry
-
Sector
-
Employees
104

Earnings

Latest Release
Nov 05, 2020
EPS / Forecast
-- / -0.28
Revenue / Forecast
-- / 16.90M
EPS Revisions
Last 90 days

STML_old Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.